Antiplatelet therapy before, during, and after extremity revascularization

Jane K Yang; Juan Carlos Jimenez; Sinan Jabori

doi:10.1016/j.jvs.2014.07.006

Antiplatelet therapy before, during, and after extremity revascularization

J Vasc Surg. 2014 Oct;60(4):1085-91. doi: 10.1016/j.jvs.2014.07.006. Epub 2014 Aug 8.

Authors

Jane K Yang¹, Juan Carlos Jimenez², Sinan Jabori²

Affiliations

¹ Division of Vascular Surgery, University of California, Los Angeles, Los Angeles, Calif. Electronic address: jkyang@mednet.ucla.edu.
² Division of Vascular Surgery, University of California, Los Angeles, Los Angeles, Calif.

PMID: 25124360
DOI: 10.1016/j.jvs.2014.07.006

Abstract

Peripheral arterial disease (PAD) is well recognized as a marker for systemic atherosclerosis. Platelets play an essential role in all stages of the disease, contributing to both thrombosis and the development of atherosclerosis. Medication regimens to optimize outcomes in both patients who are to undergo revascularization and those who will be managed without interventional therapy must address antiplatelet therapy. Given the common cardiovascular and cerebrovascular comorbidities in patients with PAD, antiplatelet therapy has the potential to decrease thromboembolic events in addition to improving patency after interventions. This clinical update reviews the current literature and recommendations for antiplatelet therapy in patients with PAD.

Publication types

Review

MeSH terms

Humans
Perioperative Care / methods*
Peripheral Arterial Disease / drug therapy*
Peripheral Arterial Disease / surgery*
Platelet Aggregation Inhibitors / therapeutic use*
Vascular Surgical Procedures*

Substances

Platelet Aggregation Inhibitors